Rare Sugar Members Trigger Glucagon-Like Peptide-1 Release and Inhibit Food Intake in Mice

Why this study matters

D-allulose did something in mice that most low-calorie sweeteners don't. It raised active GLP-1 in the portal vein and cut food intake. That puts this rare sugar in a different conversation.

The study, published in Nutrients (DOI 10.3390/nu17071221), treats rare sugars as more than just sweet-tasting molecules.

Background: rare sugars

Rare sugars occur naturally in small quantities. They deliver sweetness with a low calorie load. That is why they have been called next-generation functional sugars.

The question was whether they also do metabolic work. This paper says yes, at least for D-allulose.

What the study did

Researchers gave mice a single oral gavage of D-allulose at 1 g/kg and 3 g/kg. They measured active GLP-1 in portal plasma. Portal plasma is blood leaving the gut, where GLP-1 signals first.

They also tracked short-term food intake. Then they tested cause and effect. They added a GLP-1 receptor antagonist called exendin(9-39). If D-allulose suppressed feeding through GLP-1 signaling, blocking the receptor should blunt that effect. That is exactly what happened.

Key findings

Condition	What happened
D-allulose, 1 g/kg oral gavage	Significant rise in portal active GLP-1
D-allulose, 3 g/kg oral gavage	Significant rise in portal active GLP-1
D-allulose alone, short-term feeding	Dose-dependent suppression of food intake
D-allulose + exendin(9-39)	Feeding suppression blocked

The last row matters most. The feeding effect is not a vague gastric event. It depends on GLP-1 receptor signaling. Block the receptor, block the satiety signal.

What it means for manufacturers

This is not just another low-calorie-sweetener data point. The paper's conclusion links D-allulose to preventing overeating and supporting glycemic control. That gives rare sugar suppliers a functional story, not just a sugar-replacement story.

For a formulator, the practical questions are dose and context. The study used an acute gavage dose in mice. That is not the same as a serving of a beverage or bar. But the mechanism gives a reason to think about D-allulose beyond sweetness. A small amount in a product might do more than replace bulk sugar. It might support the body's own GLP-1 response.

Rare sugars remain a broad category. The mechanistic evidence here centers on D-allulose. Other rare sugars may behave differently. Still, this points toward product concepts where satiety and glucose control are the goal. Think meal replacements, high-protein snacks, or functional beverages aimed at appetite control.

No one should confuse D-allulose with a GLP-1 drug. The effect is short-term. The study is in mice. But the mechanism is real, and the receptor-blocking experiment gives it weight.

Questions formulators ask

Is the GLP-1 effect proven in humans?

Not in this paper. The evidence comes from mice. Human studies would need to confirm the response at realistic serving sizes.

What dose did the mice receive?

They received 1 g/kg or 3 g/kg body weight by oral gavage. That is a high acute dose. It tells you the effect exists, not the minimum effective dose in food.

Can D-allulose replace GLP-1 medications?

No. It is a food ingredient, not a pharmaceutical. Its potential is in everyday products that support appetite and glucose control.

Rare sugar suppliers now have a stronger story. D-allulose is not just a sweetener. It is a sweetener with a measurable gut hormone effect. For manufacturers, that opens the door to positioning products around satiety and post-meal glucose. More work remains. The direction is clear.